Contracts › 75F40124F80370
75F40124F80370: Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Biologic Effectiveness and Safety (BEST) Innovative Methods (IM) Program Cor: Brian Hively Brian.Hively@Fda.Hhs.Gov 3-WAY Cost (Requires Co/Cs Approval)
Awarded to The Mitre Corporation by Food and Drug Administration (FDA).
$6.6Mobligated
$10.7Mpotential value
29 September 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40124F80370 |
|---|---|
| Vehicle | 75FCMC23D0004 |
| Awardee | The Mitre Corporation |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | R425 Support- Professional: Engineering/Technical |
| Place of performance | VA |
| Period of performance | 27 September 2024 to 29 September 2026 |
| Potential end | 29 September 2027 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record